The Impact of Market Volatility on the Cell Therapy Industry  by Brindley, David A. et al.
Cell Stem Cell
ForumThe Impact of Market Volatility
on the Cell Therapy IndustryDavid A. Brindley,1,2,3,7,* Brock C. Reeve,2 William A. Sahlman,3 Greg A. Bonfiglio,4,5 Natasha L. Davie,1,2,6,7
Emily J. Culme-Seymour,7 and Chris Mason1,7
1The Advanced Centre for Biochemical Engineering, University College London, Torrington Place, London, WC1E 6BT, UK
2The Harvard Stem Cell Institute, Holyoke Centre, Massachusetts Avenue, Cambridge, MA 02138, USA
3Harvard Business School, Soldiers Field, Boston, MA 02163, USA
4Proteus Venture Partners, Portola Valley, CA 94028, USA
5Centre for Commercialization of Regenerative Medicine, Toronto, ON, M5G 1L5, Canada
6Harvard Medical School, Center for Excellence in Vascular Biology, Avenue Louis Pasteur, Boston, MA 02115, USA
7London Regenerative Medicine Network, Clerkenwell Green, London, EC1R 0DP, UK
*Correspondence: david_brindley@harvard.edu
DOI 10.1016/j.stem.2011.10.010
Stock market volatility in the cell therapy industry has greatly hindered the investment necessary to fund
translational therapies. Here, we review the volatility of leading companies and suggest that a distinct
industry is maturing to a point at which the volatility should subside, providing a more attractive environment
for future growth.Annual revenues for the global cell
therapy industry have surpassed $1 billion
(Mason et al., 2011); however, growth has
been constrained by a number of bottle-
necks, particularly funding. A decade
(1991–2001) of overly exuberant invest-
ments and multibillion-dollar losses
based on science not yet ready for trans-
lation made investors cautious (Mason,
2007). Today, however, the industry has
greatly matured and there is tangible
evidence of an overall strong track record
of growth. Nonetheless, the industry is
viewed as high-risk and funding remains
a major challenge. Without stable and
sustained investment, commercial trans-
lational research will continue to be
stalled.
Therapeutic companies are typically
initially funded by a combination of angel
and venture capital investment. As
a company develops and its products
progress to clinical trials, additional fund-
ing is needed. In order to raise this later-
stage funding, one of two routes is typical:
engaging in a strategic partnership with
a multinational company or selling a
percentage of the company as shares on
the stock market. Once shares are publi-
cally traded, they, and the company itself,
are subject to investor scrutiny. Two
highly visible measures of an industry’s
growth and stability are the stock prices
of representative companies and the
volatility of those prices (the dispersion
about their historic mean). For example,
shares in Dendreon (Seattle, WA, USA),a developer of immunotherapies for
cancer and the largest company by
market capitalization in the cell therapy
sector, recently plummeted by 67% in
1 day in response to a reduction in pre-
dicted revenues from $350 million to
probably nearer $260 million. Such a
dramatic drop in share price could under-
standably make existing and prospective
cell therapy industry investors wary,
although as we discuss below, high vola-
tility, especially in emerging industries,
does not necessarily lead to high risk or
poor returns. Nonetheless, minimizing
turbulence can improve investor confi-
dence, and in order to survive and grow,
the industry must identify and address
the underlying drivers of such volatility.
Volatility Driven by Short-Term
Uncertainty
The plummet in Dendreon’s share price
was undoubtedly compounded by the
perceived risk of cell therapy industry in-
vesting in general. Moreover, this is not
an isolated event. Geron (Menlo Park,
CA, USA) has a mixed portfolio of late-
stage biopharmaceuticals and early-
stage cell therapies, atypical for the cell
therapy industry. Despite the more minor
role, Geron’s involvement in cell therapy
has contributed to disproportionate vola-
tility in its stock and that of the broader
industry. In 2009, the FDA placed Geron’s
proposed trial of GRNOPCI, an embry-
onic-stem-cell-derived therapy for spinal
cord injuries, on clinical hold. FollowingCell Stem Cell 9,the FDA announcement, Geron’s stock
dropped by over 10%, with the knock-
on effect of wiping hundreds of millions
of dollars off the market capitalization of
the entire cell therapy sector. Similar
market volatility ensued when the clinical
hold was lifted in mid-2010 and Geron’s
stock price rose by 17% in 1 day. Simi-
larly, when Osiris (Columbia, MD, USA)
discontinued its phase three trial of Pro-
chymal, an adult stem cell treatment for
Crohn’s disease, its share price dropped
despite the fact that the company’s stra-
tegic partner (Genzyme, Cambridge, MA,
USA) maintained robust support.
Most investors seek long-term value,
yet the extreme investor reactions high-
lighted above show that in the cell therapy
industry, investors are swayed by
announcements that have largely short-
term impacts, even though these may
turn out to be minor setbacks that
precede long-term growth. This is likely
due to the lack of historical financial data
specific to the cell therapy industry; yet,
wewould argue that over the past 5 years,
the industry has accumulated a rich body
of data, especially from publically traded
companies, that can be used to compare
historical performance to key bench-
marks, including the broader biotech
and pharmaceutical industries. Exploring
this data and identifying trends could
offer much more insight for investors
about the overall health and growth of
the industry than focusing on the short-
term activity of individual companies.November 4, 2011 ª2011 Elsevier Inc. 397
Table 1. Cell Therapy Industry Cumulative Growth Index: September 2006–September 2010
Percentage Growth
Company 5 Years 4.5 Years 4 Years 3.5 Years 3 Years 2.5 Years 2 Years 1.5 Years 1 Years
Advanced Cell
Technologies
77.46 81.82 51.52 23.81 300.00 45.45 23.08 60.00 128.57
Aastrom Biosciences 72.71 76.44 70.50 37.02 11.49 0.76 18.13 63.75 75.84
Athersys * * 72.18 47.07 13.55 294.55 126.04 35.03 23.59
Bionet Corp * * 53.53 29.85 23.57 12.15 38.84 27.86 10.99
BioSante 14.22 62.43 57.02 20.92 49.21 99.22 33.16 46.86 83.57
BioTime 2185.71 757.14 1400.00 1500.00 168.16 228.77 41.59 7.51 8.84
Brainstorm Cell Therapies 22.58 13.64 58.70 24.00 46.15 322.22 80.95 15.15 80.95
China Cord Blood * * 38.53 40.39 43.12 41.23 52.82 33.00 19.66
Cord Blood America 99.34 99.48 99.08 96.47 92.31 93.10 80.00 93.33 86.96
Cryo-Cell International 3.85 20.00 77.63 217.65 297.06 390.91 16.88 92.86 200.00
Cytori 41.62 43.33 40.38 50.08 52.45 29.17 2.31 56.58 35.42
Dendreon 144.65 181.09 51.08 128.65 101.87 310.00 48.21 63.43 68.91
Fibrocell Science * * * * * * * 34.69 8.57
Geron 57.93 61.07 60.75 38.00 36.93 24.94 57.18 48.86 39.67
Immunocellular * 34.42 51.61 101.43 107.35 464.00 101.43 65.88 56.67
International Stem Cell * * 6.98 43.75 155.56 100.00 12.20 41.40 14.81
Mesoblast 525.20 293.07 387.12 931.17 525.20 905.06 735.79 309.28 329.19
Neostem 89.43 80.53 84.74 54.04 21.28 32.14 60.00 47.14 55.15
Neuralstem * * 61.76 61.27 30.29 32.61 14.02 38.38 37.11
Nuvasive 29.37 13.72 17.78 23.68 44.49 8.25 33.03 33.07 32.75
Opexa Therapeutics 74.06 70.89 70.43 2.96 39.07 336.67 0.76 35.15 16.96
Osiris Therapeutics 53.38 62.70 60.57 50.91 67.18 68.82 64.56 38.21 26.16
Pluristem Therapeutics * 85.28 73.50 1.85 162.38 99.25 93.43 134.51 140.91
ReNeuron * * * * * * * 16.52 6.93
StemCells 89.44 90.39 88.92 83.60 79.84 82.55 85.00 79.15 69.25
Tengion * * * * * * * * 75.38
TiGenix * * 86.95 84.62 82.11 74.72 84.55 80.63 51.08
Cell Therapy Industry
Cumulative Growth Index
141.89 22.37 39.18 105.47 49.04 138.51 27.41 0.83 17.00
S&P 500 8.13 14.16 19.13 9.53 5.73 72.97 20.68 7.95 11.49
NASDAQ 16.09 5.90 3.20 12.73 8.38 92.47 29.31 11.98 16.96
NASDAQ Biotechnology
Index
29.85 27.09 18.75 25.36 11.90 58.93 23.20 9.16 18.02
NYSE ARCA
Pharmaceutical Index
10.86 7.90 7.84 2.79 1.10 43.48 12.26 3.28 7.85
Sept. 2006 March 2007 Sept. 2007 March 2008 Sept. 2008 March 2009 Sept. 2009 March 2010 Sept. 2010
Year % High 2185.71% 757.14% 387.12% 931.17% 525.20% 905.06% 735.79% 309.28% 329.19%
Year % Low 99.34% 99.48% 99.08% 96.47% 92.31% 93.10% 84.55% 93.33% 86.96%
Year % Range 2086.37% 657.66% 288.04% 834.70% 432.89% 811.96% 651.24% 309.28% 242.23%
All data is correct as published on 1st September 2011. All historical data obtained is the adjusted closing price of stocks as published on the trading
day closest to either the 1st of September or the 1st of March of the appropriate year, which therefore accounts for any stock splits and distributions.
Data has not been adjusted for inflation. Foreign exchange fluctuations need not be accounted for because any comparison is based on percentage
changes in share price in the quoted currency of the stock. (*), company pre-IPO.
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2006–September 2010
Table 1 compares the performance of the
majority of publically quoted cell therapy
companies over the past 5 years to that398 Cell Stem Cell 9, November 4, 2011 ª20of major indexes. Cell therapy companies
are strictly defined as companies devel-
oping or deploying living cells as implant-
able therapies regardless of the clinical
indication (Mason et al., 2011). Our anal-11 Elsevier Inc.ysis suggests that the sector has grown
strongly, but not smoothly. Growth is not
consistent across the timeline for single
companies or between companies for
identical periods, thus highlighting the
Figure 1. Cell Therapy Industry Cumulative Growth Index Compared to Major Financial Indexes (September 2006–September 2010)
This figure plots the Cell Therapy Industry Cumulative Growth Index for the last 5 years against major technology, biotech, and pharma indexes.
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Forumsector’s fragmented volatility. This
suggests that although market news
impacts the entire sector, it is not the
only dominant force driving the industry’s
overall growth trajectory. Surprisingly,
events in established markets have had
limited impact on the publically quoted
cell therapy industry, which has overall
continued to grow despite poor returns
in global markets over the same period.
We produced a growth index for the cell
therapy industry (Cell Therapy Industry
Cumulative Growth Index) using the value
line index methodology. All stocks are
weighted equally irrespective of relative
share price or market capitalization,
which can be a poor indicator of the
future impact of a given company on
the broader sector because long term
titans have yet to emerge (Sahlman and
Stevenson, 1985).
Figure 1 plots the Cell Therapy Industry
Cumulative Growth Index for the last 5
years against major technology, biotech,and pharma indexes. The overall trend is
initially one of high volatility, possibly
normalizing since late 2009 toward
pharma/biotech levels. This overall
decrease corresponds to a progressive
reduction in the range of the underlying
company growth data. Taken together,
the reduction in the Cell Therapy Industry
Cumulative Growth Index volatility and
the convergence of the underlying data
might suggest that the cell therapy sector
is starting to emerge from a period of
high volatility toward a more predictable
phase.
Although our analysis suggests strong
historic growth since 2006, it is notable
that this growth is in part dependent
upon the gradual increase in the number
of cell therapy companies being publicly
traded. In addition, the increasing port-
folio size reducesoverall volatility because
the impact of individual company fluc-
tuations is distributed across a larger
sample.Cell Stem Cell 9,Factors Contributing to Volatility
in the Cell Therapy Industry
As discussed above, reducing volatility in
the cell therapy sector would improve
investor confidence and thus encourage
future investment. In our view, the under-
lying causes of volatility in the cell therapy
industry can be divided into three classes:
causes common to emerging technolo-
gies; volatility unique to the current global
economic crisis; and causes unique to the
cell therapy industry.
Volatility Common to Emerging
Technologies
Historically, every new discovery and
technology experiences market volatility.
From the bursting of the South Sea
Bubble in 1720 to the dot com crash of
2000, no new industry is immune to
hype followed by exaggerated despon-
dency once reality sets in. The cell therapy
industry had its own first-generation
bubble bursting in 2001 (Mason, 2007).
This type of hype-cycle is an inherentNovember 4, 2011 ª2011 Elsevier Inc. 399
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Forumcomponent of an emerging, disruptive
technology and its subsequent product
development cycle (Fenn and Raskino,
2008). For a sustainable industry to mate-
rialize, initial volatility followed by stability
and major growth is the norm.
Volatility Unique to the Current
Economic Situation
Although cell therapy is a distinct industry
from biotech and pharma, and it behaves
independently of other sectors such as
alternative energies and nanotechnology,
it still seeks capital from finite reserves.
The era of cheap, easily available venture
funding has ended. Biotech has in partic-
ular been badly hit by this change, result-
ing in a ‘‘valley of death’’ between high-
quality basic discovery and its translation
into commercial patient therapies (Cook-
sey, 2006). Given their limited resources,
investment timescales, and large range
of investment opportunities, venture capi-
talists (VCs) are increasingly risk averse
and anxious to see clear exit strategies
in the shortest possible timeframes
(Mason and Manzotti, 2010).
The global financial markets are pres-
ently highly volatile themselves and the
uncertain outlook challenges all indus-
tries, including cell therapy. In this situa-
tion, VCs find it more difficult to raise
money to fund new and existing portfolio
companies and governments worldwide
are faced with deficits and cuts that chal-
lenge their potential ability to fund transla-
tional research (Rao, 2011).
Volatility Unique to the Cell Therapy
Industry
To date, factors unique to the cell therapy
industry are still poorly understood. As
a result, they contribute significantly to
industry volatility because their inherent
risks and the manner in which they may
interact are unknown. Moreover, the
interaction of these factors is likely to be
multiplicative, yielding additional and
unforeseeable causes of volatility.
One clear factor that is unique to the
cell therapy industry, at least within the
healthcare sector, is the potentially
disruptive nature of this technology. The
cell therapy industry is based upon
a number of different technologies that
target numerous clinical indications, with
varying degrees of potential efficacy,
ranging from life-changing therapies to
outright cures. The commercial impact of
this imminent treatment revolution and its
infrastructural demands are unknown.400 Cell Stem Cell 9, November 4, 2011 ª20There are no precedents in the healthcare
sector that match the disruptive nature
of cell therapy technology on patients,
healthcare providers, and governments.
Subsequently, it is difficult to predict its
likely impact (McKernan et al., 2010).
Attempting to forecast industry growth
based on such disruptive technologies
is known to result in an underassess-
ment of the inherent risks and opportuni-
ties (Christensen et al., 2000). This is
already demonstrated by the limited
relationship between cell therapy market
behavior and established technology-
based benchmarks.
Another issue for the cell therapy
industry is its interdependence. Due to
the lack of historical market data and the
small number of analysts monitoring
the industry, limited infrastructure, and
small number of companies, all organiza-
tions in the cell therapy industry are
interdependent to varyingdegrees. There-
fore, as seen in the market response to
Dendreon’s projected revenue shortfall,
the health of a single public company
can impact upon the health of the entire
sector—at least in the short term.
This sector interdependency is not
restricted to the public markets. Due to
the early stage of the industry and current
aversion to stock market floatations,
a significant proportion of cell therapy
companies are privately owned and
financial information regarding these
companies is often restricted, in contrast
to public companies. Privatemarket trans-
actions can significantly impact sentiment
in the public markets, however, as ob-
served in the recent $750 million acquisi-
tion of Advanced BioHealing (San Diego,
CA, USA) by Shire (Dublin, Ireland), which
promoted investor interestandconfidence
in the cell therapy industry, reflected by
modest short-term stock price increases
for other leading companies.
It is vital that as the industry grows and
market data accumulates, attention is
paid to uncovering the underlying causes
of remaining volatility, particularly those
that appear unique to this sector, because
this is necessary to prevent such volatility
moving forward.
Conclusion
Our data is suggestive of two interpreta-
tions. Firstly, given the recent trend since
late 2009, it could be argued that the cell
therapy industry is emerging from an11 Elsevier Inc.era of volatility and hype towards a period
of robust growth and the widespread
delivery of life-changing therapies to
patients. Alternatively, high volatility
may remain the norm and the recent
decrease in volatility of the Cell Therapy
Industry Cumulative Growth Index will
not be maintained. Regardless of which
interpretation turns out to be correct, the
key underlying factors for fully resolving
volatility will still need to be conclusively
addressed, including sustainable fund-
ing, scalable and cost-effective manu-
facturing, efficient clinical trial pathways,
appropriate regulation, suitable reim-
bursement, and proven business models.
Compounding the causes that we outline
are broader issues relating to public
knowledge and perception, investor con-
fidence, ethical challenges, and the need
for increased public investment in infra-
structure and the creation of intellectual
capital.
A fertile and profitable environment for
cell therapy innovation is emerging, driven
by the growing number of publically
funded translation-related initiatives and
centers, including A*Star, Berlin-Bran-
denburg Center for Regenerative Thera-
pies, California Institute for Regenerative
Medicine, Canadian Center for Regenera-
tive Medicine, Fraunhofer IZI, Harvard
Stem Cell Institute, Karolinska Institute,
McGowan Institute for Regenerative
Medicine, National Centre for Regenera-
tive Medicine (Case Western Reserve),
and NIH Centre for Regenerative Medi-
cine Institute. These organizations aim to
de-risk cell-based products and services
to the point where their potential is quan-
tified rather than speculative. Removing
the hype surrounding a new product or
service and enabling a predictable route
and time to market will undoubtedly help
smooth potentially volatile, ill-informed
investor activity. It is encouraging to note
that many of the above translation centers
are in the process of linking up to provide
a global supercluster: the Regenerative
Medicine Consortium. Global organiza-
tions such as ISSCR and ISCT, as well
as industry groups including the Alliance
for Regenerative Medicine and the Bio-
Industry Association (BIA), all have signif-
icant roles to play. By acting responsibly
and proactively rather than reactively,
they will further damp down the potential
for market overreaction to news both
good and bad.
Cell Stem Cell
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tionary; however, every member of the
cell therapy community has a role in
ensuring that they react appropriately to
sector announcements, be they ground-
breaking science or first-in-man clinical
trials. It is important to look beyond short-
term volatility and identify robust historic
growth and opportunities to sustain this
growth in the future. As the number of
‘‘early wins’’ grows and historical market
data becomes available, the interdepen-
dency of companies in the cell therapy
sector, public and private, will decline.
Moreover, as the industry matures, its
investor base will transition from individual
speculators seeking short-term gains to
institutional investors seeking long-term
value, thereby ensuring more consistent
funding and reducing industry volatility.
Safe, effective, and affordable patient
therapies; job creation; and wealth gener-
ation are the goals of the entire industry.
Now is the time for all stakeholders—scientists, clinicians, business people,
investors, and governments—to take full
responsibility for the future stability of
the market and thus enable cell therapies
to flourish. There are still many hurdles
that stand in the way of progress, but
excessive and damaging stock market
volatility need not be one of them.ACKNOWLEDGMENTS
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